Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Janus Henderson Group PLC London, X02.19MShares$947 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$903 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$862 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$854 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$811 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.88MShares$810 Million10.35% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$617 Million0.01% of portfolio
-
State Street Corp Boston, MA691KShares$299 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD508KShares$220 Million0.02% of portfolio
-
Ubs Group Ag506KShares$219 Million0.03% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 09
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,279
-6.63%
|
$3,239,155
$445.63 P/Share
|
|
Aug 21
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
7,616
-3.27%
|
$3,046,400
$400.51 P/Share
|
|
Aug 20
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
59,901
+0.24%
|
$23,001,984
$384.95 P/Share
|
|
Aug 18
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
105,782
+0.31%
|
$38,504,648
$364.61 P/Share
|
|
Aug 18
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
1,304
-1.64%
|
$483,784
$371.08 P/Share
|
|
Aug 15
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
10,000
-22.74%
|
$3,650,000
$365.89 P/Share
|
|
Aug 15
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+44.2%
|
$160,000
$16.46 P/Share
|
|
Aug 13
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
129,172
-2.97%
|
$47,276,952
$366.29 P/Share
|
|
Aug 13
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
129,172
+28.99%
|
$1,162,548
$9.45 P/Share
|
|
Aug 12
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
43,605
-2.07%
|
$15,479,775
$355.37 P/Share
|
|
Aug 12
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,605
+15.89%
|
$392,445
$9.45 P/Share
|
|
Aug 12
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
43,263
-0.89%
|
$15,358,365
$355.31 P/Share
|
|
Aug 12
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,263
+7.9%
|
$389,367
$9.45 P/Share
|
|
Aug 11
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
3,203
-0.84%
|
$1,121,050
$350.62 P/Share
|
|
Aug 11
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,203
+1.65%
|
$28,827
$9.45 P/Share
|
|
Aug 11
2025
|
Rebecca Taub Director |
SELL
Open market or private sale
|
Direct |
3,200
-0.34%
|
$1,120,000
$350.6 P/Share
|
|
Aug 11
2025
|
Rebecca Taub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,200
+0.68%
|
$28,800
$9.45 P/Share
|
|
Aug 01
2025
|
Daniel J. Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
967
+50.0%
|
-
|
|
Jul 18
2025
|
Paul A Friedman Director |
SELL
Open market or private sale
|
Direct |
1,400
-0.74%
|
$490,000
$350.03 P/Share
|
|
Jul 18
2025
|
Paul A Friedman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+0.74%
|
$12,600
$9.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 45.2K shares |
|---|---|
| Open market or private purchase | 166K shares |
| Exercise of conversion of derivative security | 427K shares |
| Open market or private sale | 403K shares |
|---|---|
| Bona fide gift | 15K shares |